Article
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
Antimicrobial agents and chemotherapy - 9 Jul 2024
Moeck Greg, Gasink Leanne B, Mendes Rodrigo E, Woosley Leah N, Dorr MaryBeth, Chen Hongzi, Wagenlehner Florian M, Henkel Tim, McGovern Paul C
Abstract excerpt
CERTAIN-1 was a Phase 3, double-blind, randomized, parallel group study of the efficacy and safety of cefepime-taniborbactam versus meropenem in the treatment of adults with complicated urinary tract infection (cUTI), including acute pyelonephritis. We determined susceptibility of Enterobacterales and Pseudomonas aeruginosa baseline pathogens to cefepime-taniborbactam and comparators and characterized β-lactam...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.